L'intérêt à découvert pour Intuitive Surgical donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Intuitive Surgical. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Intuitive Surgical (NASDAQ:ISRG) Stock, Rapport sur les intérêts à découvert

Intuitive Surgical

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.

Intuitive Surgical Inc

INTUITIVE SURGICAL ORD

<p><strong>Stryker</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) is a medical device company that has risen to become the third-largest U.S. firm in the healthcare equipment and supplies industry. The company has often acquired other firms to boost its competitiveness and add capabilities. Still, recent months in 2024 have been particularly active for Stryker when it comes to acquisitions.</p>
<p>Since the beginning of July, the company has closed on or announced purchases of five companies. I&#39;ll dive into what Stryker does and the most important of these acquisitions to help determine whether they make the stock a buy.</p>
<h2><strong>Stryker: A Highly Diversified Medical Device Company</strong></h2>
<p>Stryker has two reportable segments: MedSurg &amp; Neurotechnology and Orthopedics &amp; Spine. MedSurg provides surgical tools, including minimally invasive devices. These include small cameras used in surgeries. Neurotechnology offers tools for skull and brain surgeries, including stroke treatments. In 2023, this segment accounted for 58% of the company&#39;s total revenue.</p>
<p>The other segment revolves around bodily implants. Orthopedics includes hip, knee, and shoulder implants to replace these joints. The company&#39;s Mako system provides robotics-assisted replacement of these joints. It has similarities to <strong>Intuitive Surgical</strong>&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) da Vinci system, but the two specialize in different treatment areas.</p>
<p>This segment also provides trauma and extremity implants. Trauma refers to implants used to help repair large broken bones like those in the arms and legs. Extremity implants help repair joints and bones in the hands and feet. It also provides spinal implants. This segment accounted for 42% of revenue in 2023.</p>
<h2><strong>Breaking Down Stryker&#39;s Recent Acquisitions</strong></h2>
<p>I&#39;ll focus on two of Stryker&#39;s recent acquisitions, NICO and Care.ai.</p>
<p>The NICO acquisition now gives Stryker ownership of minimally invasive devices that are used to surgically treat intracerebral hemorrhage (ICH). ICH is the deadliest form of stroke and affects 3.4 million people annually. The current care standard for ICH is medical management. This means doctors keep the patient stable while they hope the body can remove the blood clot over time.</p>
<p>The New England Journal of Medicine published a study where the NICO technology cut patient mortality rates by nearly in half compared to medical management. Additionally, the patients treated using NICO had significantly better quality of life outcomes. Given the large number of patients who suffer from ICH and the impressive efficacy of NICO technology, this feels like a strong purchase.</p>
<p>The care.ai purchase allows Stryker to offer its hospital and health provider customers tools to more efficiently monitor the status of patients. This allows these customers to make better decisions about how to allocate resources across patients. For example, patients can use AI chatbots to assess their condition. They can check whether they need urgent medical care or not.</p>
<p>The company&#39;s technology can also improve the monitoring of patients while they are in the healthcare facility. Its &quot;smart room&quot; technology involves installing sensors that use AI to better monitor the condition of patients. These features can help Stryker&#39;s customers better prioritize staff and resources in a facility. They aim to improve patient outcomes and satisfaction.</p>
<p>Overall, this could create value for Stryker customers. However, I am less sold on it compared to NICO. Just because a company uses AI in its offerings doesn&#39;t mean it is truly providing differentiated value compared to what already exists.</p>
<p>In the near term, these acquisitions will not impact the company&#39;s financial results. This is likely the case, as the financial details of these acquisitions were not disclosed. The Securities and Exchange Commission (SEC) does not require publicly traded companies to disclose these details unless the acquisitions are expected to have a material impact on the company&#39;s financial statements. Still, they could definitely create value for the company over the long term.</p>
<p>I especially like the NICO acquisition, and it could be a good thing that the company did not have to disclose the price. It might suggest that they were able to acquire the asset at a reasonable cost.</p>
<h2><strong>Stryker Is Expected to See Robust Earnings Growth</strong></h2>
<p>Analysts expect strong earnings growth over the next two years, especially versus its peers. Analysts expect a 12% annual growth in trailing twelve months earnings per share. That is over double the rate of one of its main competitors, <strong>Medtronic</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mdt#NYSE">MDT</a>).</p>
<p>Two Wall Street analysts raised their price target for Stryker in October. Their average price target implies an upside of 7% for the stock. Stryker remains a strong player in its industry, but these acquisitions don&#39;t move the needle on the stock for me right now.</p>
<p>The article &quot;<a href="https://www.marketbeat.com/originals/strykers-acquisition-spree-double-digit-growth-on-the-horizon/">Stryker&#39;s Acquisition Spree: Double-Digit Growth on the Horizon</a>&quot; first appeared on MarketBeat.</p>


Earnings

Large Cap

News

Price Target

Offerings

Markets

Analyst Ratings

Trading Ideas

ISRG

Stryker's Acquisition Spree: Double-Digit Growth on the Horizon

<p>JP Morgan  analyst Robbie Marcus   maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $495 to $575.</p>


JP Morgan Maintains Overweight on Intuitive Surgical, Raises Price Target to $575

<p>RBC Capital  analyst Shagun Singh   maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Outperform and raises the price target from $515 to $525.</p>


RBC Capital Maintains Outperform on Intuitive Surgical, Raises Price Target to $525

<p><strong>Labcorp Holdings, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lh#NYSE">LH</a>) or Labcorp benefits from the solid execution of its strategic priorities. Investment in targeted high-growth areas should drive the momentum. The company faces headwinds from macroeconomic uncertainties and growing foreign exchange issues. The stock carries a Zacks Rank #3 (Hold) currently.</p>
<h2>Factors Driving LH Stock</h2>
<p>LabCorp is well-placed for long-term success in Cell &amp; Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business. In June 2024, Labcorp Tissue Complete comprehensive genomic profiling (CGP) service was availed in Geneva and Shanghai to support global clinical trials. The integration of OmniSeq INSIGHT circulating tumor DNA expanded Labcorp&#39;s leadership in liquid biopsy comprehensive genomic profiling for solid tumors.</p>
<p>LabCorp&#39;s Biopharma business is benefiting from collaborations with leading pharmaceutical and biotechnology companies with whom it started to work on potential antivirals, treatments and vaccines. Revenue-wise, Biopharma&#39;s growth continues to be driven by strength in central laboratories, its largest part, which improved by 9% in the second quarter of 2024. The Early Development business is also recovering sequentially, led by reduced cancellations and booking improvement, and is expected to generate higher revenues in the second half of the year.</p>
<p>Labcorp has been focused on expanding its margins though the LaunchPad initiative. The company&#39;s 2024-2026 guidance includes a savings target range of $100 million-$125 million annually. The benefits will be driven by rationalizing the geographic location of facilities and talent, leveraging technological advancements and structural enhancements, integrating acquisitions and re-engineering the company&#39;s systems and processes. In the second quarter, the rise in operating income and margin was fueled by the strong demand and LaunchPad savings.</p>
<p>The stock has risen 11.1% in the past three months against the industry&#39;s 2.7% decline. With the company strategically expanding in the high-growth areas, as well as putting focus on cost saving initiatives, we expect the stock to continue its upward movement in the coming days.</p>
<div class="chart_embed">
<h2>Labcorp Price</h2>
<p><img alt="Labcorp Price" src="https://staticx-tuner.zacks.com/images/charts/6d/1728307858.png" style="height:251px; width:545px" title="" /></p>
<p><span style="font-size:13px">Labcorp price</span><span style="font-size:13px"> | </span><span style="font-size:13px">Labcorp Quote</span></p>
</div>
<h2>Factors Weighing on LH Stock</h2>
<p>Labcorp&#39;s operation is heavily dependent on the demand for diagnostic testing and drug development services from patients, physicians, hospitals, medical device companies and others. Volatilities in global economic conditions, including inflation and the risk of short or long-term recessions, could reduce the demand for these services, affecting the customers&#39; ability to pay and, consequently, the profitability of the company.</p>
<p>Added to this, the escalation of the present geopolitical situations in Ukraine and the Middle East can potentially decrease testing volumes, cause disruptions in the supply chain and services and increase the prices of offerings. In the second quarter, the cost of revenues went up by 4.7% year over year. SG&amp;A expenses increased 10.3%, mainly from higher personnel costs.</p>
<p>Labcorp&#39;s huge exposure in international markets makes it vulnerable to currency fluctuations. In 2023, the BLS segment derived nearly 58% of its revenues from overseas, while Dx also earned a modest portion in Canada and a relatively small amount in the rest of the world. An approximate 13.7% of the company&#39;s revenues were denominated in currencies other than the U.S. dollar in the first half of 2024. With the recent upward trend observed in the value of the U.S. dollar, further acceleration expected by analysts in this value will cause the company&#39;s revenues to face a tough situation overseas.&nbsp;In the second quarter, BLS and Dx revenue growth was partially offset by unfavorable foreign currency translation of 0.1%.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group&nbsp;and Quest Diagnostics. While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Quest Diagnostics carries a Zacks Rank #2 (Buy).</p>
<p>Intuitive Surgical&#39;s shares have surged 60.5% in the past year. Estimates for the company&#39;s earnings have moved 5.1% north to $1.65 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 135.2% in the past year compared with the industry&#39;s 14.9% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 55.5% compared with the industry&#39;s 17.9% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2347044/labcorp-stock-gains-from-biopharma-business-amid-fx-woe?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2347044">To read this article on Zacks.com click here.</a></p>


Earnings Beats

Macro Economic Events

Guidance

Health Care

Economics

General

Laboratory Corporation Of America Holdings

Labcorp Stock Gains From Biopharma Business Amid FX Woe

<p>Momentum investing is based on the idea that stocks that have risen recently will tend to keep rising and that stocks that have fallen tend to keep falling. In 1993, researchers Narasimhan Jegadeesh and Sheridan Titman at UCLA brought the idea forward.</p>
<p>Momentum investing has held up over the past 10 years. Looking at the <strong>iShares MSCI USA Momentum Factor ETF</strong> (BATS: <a class="ticker" href="https://www.benzinga.com/stock/mtum#BATS">MTUM</a>), it&#39;s seen that the fund has outperformed the S&amp;P 500 over that period. The fund has notched a cumulative total return of 251%, versus the 245% total return of the SPDR S&amp;P 500 ETF Trust.</p>
<p>Below I&#39;ll point out three of my favorite companies that are currently considered momentum stocks.</p>
<h2>Intuitive Surgical: Revolutionizing the Operating Table</h2>
<p><strong>Intuitive Surgical</strong>&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) shares have provided a total return of 66% over the past twelve months, beating out the S&amp;P 500 by 30%. This company stands out due to the incredible products it has built. Its primary product is the da Vinci robot.</p>
<p>This is a remotely controlled robot that assists doctors in performing surgeries. Its main advantage is in reducing the human error involved in surgeries. It eliminates the risk of things like hand tremors in surgeons and can make smaller, more precise cuts than a human. This reduces the invasiveness of surgeries and allows patients to have shorter recovery times.</p>
<p>Even after being around for over 10 years, the company is still seeing very solid revenue growth, coming in at 14% last quarter. The company continues to become more and more profitable. It increased its gross margin by over 150 basis points from last year. Its operating margin rose by nearly 200 basis points. Its operating margin is higher than 91% of companies in the US healthcare sector. Its dominant market position created through its leading technology allows it to maintain and increase these margins.</p>
<h2>The Role of Artificial Intelligence in Dell&#39;s Growth Strategy</h2>
<p>Over the past twelve months, <strong>Dell</strong>&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dell#NYSE">DELL</a>) shares have returned a total of 67%. Unlike <strong>Intel</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intc#NASDAQ">INTC</a>), Dell is one of the legacy U.S. tech companies that have been able to successfully navigate the changing landscape. The rise of new technology firms and the advent of artificial intelligence necessitated that these companies shift their business toward the AI and data center vector.</p>
<p>Dell has done exactly that. Dell was traditionally known as a personal computer (PC) company. Now, nearly half its business comes from its Infrastructure Solutions Group. Within this segment, it sells AI-optimized servers to data centers. The company has seen massive growth in the sales of these servers, up 80% in just one quarter. Sales of these servers last quarter topped their combined total sales in Dell&#39;s fiscal 2024.</p>
<p>This rapid expansion is good to see, and the company still has a $3.8 billion backlog in AI server orders it is working to fulfill. Dell could start to look even better if its PC business picks up again. Growth in that business was 0% last quarter. But, it&#39;s possible growth could reignite as people and businesses need to replace aging devices and want PCs that can internally handle GenAI.</p>
<h2>Eli Lilly: Dominating Pharmaceutical Growth</h2>
<p><strong>Eli Lilly</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>) is another healthcare stock with a very strong market position. It&#39;s the world&#39;s largest drug company, with a market cap over $250 billion higher than the next closest company. Its gross and operating margins rank in the top three among the 10 largest pharmaceutical companies in the US, Canada, and Europe.</p>
<p>The company&#39;s stock has provided a total return of 66% over the past twelve months, and 295% over the past three years. It&#39;s done so largely off the back of its GLP-1 drugs for diabetes and weight loss. Mounjaro and Zepbound are leading the charge right now for Lilly. The drugs&#39; sales increased 71% and 140% in just one quarter.</p>
<p>These drugs are driving growth, but Lilly has an edge over its GLP-1 rival, <strong>Novo Nordisk</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvo#NYSE">NVO</a>). It is less reliant on its GLP-1 drugs at this point. In the first six months of 2024, these drugs accounted for over 66% of Novo&#39;s sales, compared to just 46% for Lilly. Additionally, Lilly is taking GLP-1 market share from Novo. Mounjaro and Zepbound appear to be significantly more effective in helping patients lose weight compared to Novo&#39;s Ozempic and Wegovy.</p>
<p>The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-momentum-trades-too-good-pass-up/">3 Momentum Trades Too Good Pass Up</a>&quot; first appeared on MarketBeat.</p>


Sector ETFs

Tech

ETFs

DELL

INTC

MTUM

3 Momentum Trades Too Good Pass Up

<p>Evercore ISI Group  analyst Vijay Kumar   maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a In-Line and raises the price target from $410 to $475.</p>


Evercore ISI Group Maintains In-Line on Intuitive Surgical, Raises Price Target to $475

<p>Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 10 years by 13.91% on an annualized basis producing an average annual return of 25.14%. Currently, Intuitive Surgical has a market capitalization of $171.77 billion. </p>
<p><strong>Buying $100 In ISRG:</strong> If an investor had bought $100 of ISRG stock 10 years ago, it would be worth <strong>$935.83</strong> today based on a price of $483.39 for ISRG at the time of writing.</p>
<h3>Intuitive Surgical's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727276417_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Intuitive Surgical 10 Years Ago Would Be Worth Today

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Intuitive Surgical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ISRG, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Intuitive Surgical.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 60% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $63,430, and 13 are calls, for a total amount of $740,149.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $410.0 to $495.0 for Intuitive Surgical during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Intuitive Surgical stands at 164.11, with a total volume reaching 1,028.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Intuitive Surgical, situated within the strike price corridor from $410.0 to $495.0, throughout the last 30 days.</p>
<h3>Intuitive Surgical Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727123438_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$16.9</td>
<td>$16.8</td>
<td>$16.9</td>
<td>$490.00</td>
<td>$310.9K</td>
<td style="text-align: right;">309</td>
<td style="text-align: right;">256</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$84.2</td>
<td>$80.3</td>
<td>$80.82</td>
<td>$410.00</td>
<td>$80.8K</td>
<td style="text-align: right;">152</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$16.0</td>
<td>$15.9</td>
<td>$15.9</td>
<td>$492.50</td>
<td>$39.7K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">27</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$16.5</td>
<td>$16.1</td>
<td>$16.5</td>
<td>$490.00</td>
<td>$36.3K</td>
<td style="text-align: right;">309</td>
<td style="text-align: right;">302</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$40.0</td>
<td>$38.9</td>
<td>$40.0</td>
<td>$485.00</td>
<td>$36.0K</td>
<td style="text-align: right;">169</td>
<td style="text-align: right;">82</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Surgical</h3>
<p>Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.</p>
<p>Following our analysis of the options activities associated with Intuitive Surgical, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Intuitive Surgical</h3>
<ul>
<li>With a volume of 868,586, the price of ISRG is up 0.59% at $489.07. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 24 days.</li>
</ul>
<h3>What The Experts Say On Intuitive Surgical</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $494.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Intuitive Surgical with a target price of $494. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Intuitive Surgical Unusual Options Activity For September 23

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Intuitive Surgical</strong>.</p>
<p>Looking at options history for Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) we detected 10 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 10% of the investors opened trades with bullish expectations and 60% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $154,180 and 8, calls, for a total amount of $348,579.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $455.0 to $480.0 for Intuitive Surgical over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Intuitive Surgical's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Intuitive Surgical's whale activity within a strike price range from $455.0 to $480.0 in the last 30 days. </p>
<h3>Intuitive Surgical 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726669873_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$20.2</td>
<td>$18.7</td>
<td>$19.5</td>
<td>$455.00</td>
<td>$128.7K</td>
<td style="text-align: right;">160</td>
<td style="text-align: right;">104</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$20.1</td>
<td>$20.11</td>
<td>$480.00</td>
<td>$98.5K</td>
<td style="text-align: right;">266</td>
<td style="text-align: right;">203</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.2</td>
<td>$20.2</td>
<td>$20.3</td>
<td>$480.00</td>
<td>$58.8K</td>
<td style="text-align: right;">266</td>
<td style="text-align: right;">71</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$21.3</td>
<td>$20.3</td>
<td>$20.3</td>
<td>$480.00</td>
<td>$42.6K</td>
<td style="text-align: right;">266</td>
<td style="text-align: right;">70</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$21.4</td>
<td>$20.2</td>
<td>$20.4</td>
<td>$480.00</td>
<td>$32.6K</td>
<td style="text-align: right;">266</td>
<td style="text-align: right;">49</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Surgical</h3>
<p>Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.</p>
<p>After a thorough review of the options trading surrounding Intuitive Surgical, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Intuitive Surgical Standing Right Now?</h3>
<ul>
<li>With a trading volume of 132,527, the price of ISRG is down by -0.52%, reaching $480.82.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 29 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Intuitive Surgical</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $527.0.</p>
<ul>
<li>Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Intuitive Surgical, targeting a price of $560. </li>
<li>Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Intuitive Surgical with a target price of $494. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Intuitive Surgical's Options: A Look at What the Big Money is Thinking

<p><strong>OrthoPediatrics Corp.&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kids#NASDAQ">KIDS</a>) recently launched its Enabling Technologies division, which will leverage the company&#39;s core mission of addressing unmet pediatric needs in orthopedics.</p>
<p>The advancement with the latest launch positions OrthoPediatrics at the forefront of the pediatric digital health and enabling technologies sectors.</p>
<p>Following the announcement, shares of OrthoPediatrics rose 2.15% to $32.38 on Friday. The company continues to gain a high level of synergies from its various latest developments within the pediatric digital health space. Accordingly, we expect market sentiment to continue to remain positive around this announcement.</p>
<h2>More on OrthoPediatrics&#39; Enabling Technologies Division</h2>
<p>Led by industry veteran Kevin Unger, this new division is set to differentiate OrthoPediatrics&#39; core business, generate sustainable revenue growth, and gain access to new markets and specialties beyond orthopedics.</p>
<p>The company has made significant strides in the field through its distribution of the 7D Flash Navigation System. Additionally, it collaborated with 3D Side, S.A. for patient-specific cutting guides. These innovations have laid a strong foundation for the Enabling Technologies division.</p>
<h2>OrthoPediatrics&#39; Business Advancements</h2>
<p>Given the success of the above-mentioned developments, KIDS is all set to launch its two groundbreaking technology platforms. First, Playbook is a cutting-edge surgical workflow and outcome optimization platform. It is designed to enhance surgical planning, collaboration and intraoperative workflow. Playbook is aimed at revolutionizing how surgeries are planned and executed, potentially resulting in improved outcomes and more efficient processes.</p>
<p>Second, Robotic-Assistance is for Cochlear Implant Technology.OrthoPediatrics partnered with iotaMotion, Inc. to bring a robotic-assisted insertion system to enhance cochlear implant surgery. This technology offers a slow electrode array insertion that is agnostic to cochlear implant manufacturers, providing greater control and precision for pediatric patients.</p>
<h2>Other Recent Developments by OrthoPediatrics</h2>
<p>In May, the company received the &quot;Breakthrough Device&quot; designation from the&nbsp;Food and Drug Administration&nbsp;for its new eLLi surgical device. eLLi is an implant designed to address severe pathology associated with early onset scoliosis, which can be associated with thoracic insufficiency, a potentially life-threatening condition. This innovative product should be a great addition to the suite of products for pediatric patients with scoliosis.</p>
<p>Earlier this year, OrthoPediatrics launched a new RESPONSE Rib and Pelvic Fixation system to treat children with EOS. The system represents&nbsp;OrthoPediatrics&#39;&nbsp;first solution to treat patients at risk of thoracic insufficiency syndrome. The new addition to the RESPONSE portfolio includes implants and instruments for rib and pelvic fixation, and associated devices to connect the fixation points.&nbsp;</p>
<h2>Industry Prospects Favor OrthoPediatrics</h2>
<p>Per a Grand View Research report, the global pediatric orthopedic devices market was valued at $3.83 billion in 2023 and is projected to witness a CAGR of 11.0% from 2024 to 2030.</p>
<p>Primary factors behind the projected market surge include growing awareness of orthopedic conditions in children and the rise in congenital &amp; developmental disorders. Furthermore, innovations such as adjustable &amp; customizable devices and improved materials for better functionality &amp; safety are fueling market growth.</p>
<p>Henceforth, OrthoPediatrics&#39; latest announcement is well-timed.</p>
<h2>KIDS&#39; Price Performance</h2>
<p>Year to date, shares of KIDS have risen 0.7% compared with the industry&#39;s 9.3% growth.</p>
<h2>KIDS&#39; Zacks Rank and Other Key Picks</h2>
<p>KIDS currently carries a Zacks Rank #2 (Buy).</p>
<p>Some other top-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Boston Scientific&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Boston Scientificcarries a Zacks Rank #2.</p>
<p>Intuitive Surgical&#39;s shares have surged 64.3% in the past year. Estimates for the company&#39;s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 156.9% in the past year compared with the industry&#39;s 17.5% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 57.2% compared with the industry&#39;s 19.5% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2336322/kids-stock-gains-from-its-new-enabling-technologies-division-launch?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2336322">To read this article on Zacks.com click here.</a></p>


Biotech

Mid Cap

Small Cap

KIDS

TMDX

KIDS Stock Gains From Its New Enabling Technologies Division Launch

<p><strong>Sanara MedTech Inc.&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smti#NASDAQ">SMTI</a>), along with InfuSystem Inc., recently entered into an exclusive U.S. distribution agreement with ChemoMouthpiece, LLC. Sanara will execute the terms of the agreement with the help of SI Healthcare Technologies (SI Technologies), which is a 50/50 joint venture between SMTI and InfuSystem.</p>
<p>ChemoMouthpiece owns and manufactures a clinically validated product named Chemo Mouthpiece &mdash; an oral cryotherapy device that brings relief to oral mucositis-affected patients. This device perfectly aligns with Sanara&#39;s skincare strategy. The company further aims to provide the device to oncology patients undergoing chemotherapy.</p>
<p>Following the announcement, shares of Sanara rose 0.5% to $33.51 yesterday. With the company gaining a high level of synergies from its collaborations within the skincare market, we expect market sentiment to remain positive around this development.</p>
<h2>About Sanara&#39;s Distribution Agreement With ChemoMouthpiece</h2>
<p>Under the agreement, SI Technologies will be the exclusive distributor of ChemoMouthpiece&#39;s kits in the United States. SI Technologies plans to market and distribute the product to approximately 3,000 cancer centers through InfuSystem&#39;s existing sales team. It will purchase&nbsp;the product kits from ChemoMouthpiece at a fixed price and pay a royalty on net revenues for the use of the product&#39;s intellectual property.</p>
<p>For investors&#39; note, the Chemo Mouthpiece is FDA 501(k) approved.</p>
<h2>Financial Details</h2>
<p>Sanara invested $5 million for a 6.6% ownership in ChemoMouthpiece. Sanara has drawn $15.5 million on its term loan with CRG Servicing, LLC and will fund this investment as part of that draw.</p>
<p>SI Technologies will have the option to purchase the U.S. business of ChemoMouthpiece, including all U.S. intellectual property related to the product. The purchase option will expire on Jan. 31, 2029.</p>
<h2>More on the News</h2>
<p>Oral mucositis causes painful mouth ulcers, which are a common complication of chemotherapy and radiation. The oral cryotherapy device is expected to reduce material costs for oncology treatment centers, improve patient quality of life and allow for continued treatment of cancer therapy for patients. ChemoMouthpiece is planning to publish studies in the future to reinforce the efficacy of the device.</p>
<p>Pickwick Capital Partners, LLC, served as the exclusive advisor to ChemoMouthpiece on this transaction.</p>
<h2>Recent Development by Sanara</h2>
<p>Earlier this year, Sanara signed an exclusive license agreement with Tufts University (Tufts) to develop and commercialize patented technology covering 18 unique collagen peptides.&nbsp;</p>
<p>Although Sanara has established itself as a leader in bioactive collagen peptides with CellerateRX&nbsp;Surgical Powder, the company expects to expand the CellerateRX product line and develop new bioactive collagen peptide-based applications. The recently licensed technology from Tufts helped the company to expand its offering of collagen products.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/aa/77485.jpg?v=996577913" /></p>
<p>Image Source: Zacks Investment Research</p>
<h2>Industry Prospects Favor Sanara</h2>
<p>Per a Global Market Insights report, the oral mucositis treatment market was valued at $1.6 billion in 2023 and is expected to witness a CAGR of 7.1% from 2024 to 2032.&nbsp;</p>
<p>Market growth can be attributed to the ongoing advancements in cancer therapy and the increasing prevalence of cancer. Moreover, the rising geriatric population, along with the growing demand for targeted therapies, helps the market surge.</p>
<h2>Price Performance by Sanara</h2>
<p>In the past year, shares of SMTI have lost 5.8% against the industry&#39;s 18.4% growth.</p>
<h2>SMTI&#39;s Zacks Rank and Key Picks</h2>
<p>Sanara currently carries a Zacks Rank #4 (Sell).</p>
<p>Some better-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and Boston Scientific. While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy) each, Boston Scientificcarries a Zacks Rank #2 (Buy).</p>
<p>Intuitive Surgical&#39;s shares have surged 62.2% in the past year. Estimates for the company&#39;s earnings have moved north 5.1% to $1.65 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 143.8% in the past year compared with the industry&#39;s 15.8% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 55.9% compared with the industry&#39;s 18.3% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2335233/sanara-stock-gains-from-new-us-distribution-deal-with-chemomouthpiece?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2335233">To read this article on Zacks.com click here.</a></p>


SMTI

Sanara Stock Gains From New US Distribution Deal With ChemoMouthPiece

<p><strong>ResMed Inc.</strong>&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>) growth is backed by its impressive global Mask sales growth. Of late, the company has been experiencing increased Device sales, reflecting the ongoing combined availability of AirSense 10 and AirSense 11 sleep devices.&nbsp;However, concerns loom over ResMed&#39;s escalating debt level and the adverse impact of macroeconomic challenges.</p>
<p>In the past year, this Zacks Rank #3 (Hold) company&#39;s shares have surged 66.9% compared with 16.9% growth of the&nbsp;industry.&nbsp;The S&amp;P 500 composite rose 21.1% during the same time frame.</p>
<p>The renowned medical device company has a market capitalization of $37.15 billion. ResMed projects an estimated earnings growth rate of 15.4% for 2025 compared with 15.3% of the industry. In the trailing four quarters, RMD delivered an average earnings surprise of 4.47%.</p>
<p>Let&#39;s delve deeper.</p>
<h2>ResMed: Key Upsides</h2>
<p><strong>Robust Mask Sales</strong>: ResMed continues to see strong demand for its market-leading mask portfolio. Continued product development is driving growth within this business globally. The company has successfully introduced a full suite of masks in its AirFit and, AirTouch and other ranges. It continues to witness strong growth in the U.S. Mask and accessories business, where resupply programs are powered by its digital health ecosystem, including AirView for physicians, Brightree for home care medical equipment providers and myAir for patients. RMD&#39;s recently introduced AirFit F40 performed extremely well in the United States during the fiscal fourth quarter.</p>
<p><strong>Recovery in Device Sales</strong>: ResMed&#39;s increased Device sales continue to drive overall revenue growth, reflecting the ongoing combined availability of AirSense 10 and AirSense 11 sleep devices to support the strong underlying global demand. The company has consistently witnessed strong sales within this business with the launch of its new platform of connected CPAP and APAP devices, AirSense 11.</p>
<p>Total devices accounted for approximately 52% of net revenues in fiscal 2024. Global Device sales grew 8% reportedly and 7% on a constant currency basis in the financial year. Sales of flow generator devices, including the AirSense 11 platform, grew 6% year over year globally.</p>
<h2>ResMed: Key Downsides</h2>
<p><strong>Escalating Debt Level</strong>: The company&#39;s high debt level is a concern. As of June 31, 2024, long-term debt was $697.3 million, while cash and cash equivalents totaled $238.4 million. A higher debt level induces higher interest payments, thereby increasing the risk of failure to repay debt. At the end of the fourth quarter of fiscal 2024, the company had a payout rate of 24.8%, down sequentially.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/5d/77285.jpg?v=1887241780" /></p>
<p>Image Source: Zacks Investment Research</p>
<p><strong>Challenging Macroeconomic Scenario</strong>: Global macroeconomic conditions, primarily headwinds arising from the Middle East conflict, are denting growth. Further, fluctuations in foreign currency exchange rates and volatility in capital markets could continue to affect ResMed&#39;s results of operations.&nbsp;Due to unfavorable general economic conditions, ResMed&#39;s profitability could decline and negatively impact its overall financial performance. During the fiscal fourth quarter, SG&amp;A and R&amp;D expenses rose 0.6% and 3.5%, respectively, year over year.</p>
<h2>Estimate Trend</h2>
<p>The Zacks Consensus Estimate for 2025 earnings per share has moved north 2.2% to $8.91 in the past 30 days.</p>
<p>The Zacks Consensus Estimate for the company&#39;s 2025 revenues is pegged at $5.03 billion, suggesting a 7.3% rise from the year-ago reported number.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are&nbsp;<strong>TransMedix Group</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>),&nbsp;<strong>Intuitive Surgical </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) and Boston Scientific.</p>
<p>TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. The company&#39;s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 127.9% in the past year compared with the industry&#39;s 13.9% growth.</p>
<p>TMDX sports a Zacks Rank #1 (Strong Buy) at present.</p>
<p>Intuitive Surgical, sporting a Zacks Rank of 1 at present, has an estimated long-term earnings growth rate of 17.4% compared with the industry&#39;s 13.7%. Shares of the company have risen 60.1% compared with the industry&#39;s 13.9% growth over the past year.</p>
<p>ISRG&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.</p>
<p>Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated earnings growth rate of 17.1% for 2024 compared with the industry&#39;s 15.7%. In the past year, shares of BSX have risen 52.9% compared with the industry&#39;s 16.9% growth.</p>
<p>BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.</p>
<p><a href="https://www.zacks.com/stock/news/2334520/reasons-to-retain-resmed-stock-in-your-portfolio-for-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2334520">To read this article on Zacks.com click here.</a></p>


Reasons to Retain ResMed Stock in Your Portfolio for Now

<p><strong>Intuitive Surgical's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NYSE">ISRG</a>) short percent of float has risen 10.42% since its last report. The company recently reported that it has <strong>3.74 million shares sold short</strong>, which is 1.06% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.48 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Intuitive Surgical Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726060521_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Intuitive Surgical has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Intuitive Surgical's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intuitive Surgical's peer group average for short interest as a percentage of float is 2.85%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

How Is The Market Feeling About Intuitive Surgical?

<p><strong>Trinity Biotech plc&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trib#NASDAQ">TRIB</a>) recently provided an update on its continued development of its glucose biosensor technology. Earlier this year, the company was granted a European patent for a novel method that enhances the performance of its glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of the sensor.</p>
<p>Trinity Biotech intends to use this breakthrough process to stabilize and improve the functionality of its glucose biosensor in its next-generation continuous glucose monitor (CGM) technology.</p>
<p>Shares of TRIB went down marginally by 0.05% in pre-market trading today following the news. However, as the company is gaining a high level of synergies from its continued development within the CGM market, this latest development might prove fruitful in strengthening its foothold in this space. Accordingly, we expect market sentiment to recover shortly.</p>
<h2>Significance of Trinity Biotech&#39;s Patented Process</h2>
<p>CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real time. Generally, these devices experience a &quot;run-in&quot; or &quot;settling&quot; period immediately after their insertion. During the run-in period, glucose readings are unreliable.&nbsp;</p>
<p>Trinity Biotech&#39;s patent describes a unique process within the company&#39;s reusable transmitter unit that &quot;conditions&quot; the CGM biosensor wire. This conditioning process significantly reduces this run-in time, enabling reliable measurements more quickly.&nbsp;</p>
<p>Additionally, the conditioning process has demonstrated notable improvements in the accuracy of the CGM device compared to laboratory reference methods for blood glucose testing. The process also improves the biosensor&#39;s mean absolute relative difference, which is the standard measure of accuracy used to compare CGM devices.</p>
<h2>More on the News</h2>
<p>The technology covered by this patent represents a major advancement for the company&#39;s CGM platform. The CGM technology, which Trinity Biotech acquired in January, has a unique self-inserted biosensor wire. It poses strong advantages in terms of affordability and sustainability.</p>
<p>The patented conditioning process will likely play an important role in further enhancing the CGM technology toward a more user-friendly and self-calibrating device.&nbsp;Along with other refinements to the biosensor, its wire design will be further evaluated in the upcoming pre-pivotal trials to create an optimized CGM that can be rapidly introduced into global markets.</p>
<h2>Industry Prospects Favor Trinity Biotech</h2>
<p>Per a Coherent Market Insights report, the global CGM device market was valued at $5.89 billion in 2022 and is expected to reach $12.51 billion by 2030, at a CAGR of 9.9% during the period.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d3/77157.jpg?v=1373072611" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>The market&#39;s growth is fueled by rising diabetes awareness and the increasing prevalence of diabetes among the population. The worrisome rise in the number of overweight and obese people around the world is expected to boost demand for CGM devices.&nbsp;</p>
<h2>Recent Development by Trinity Biotech</h2>
<p>In May, Trinity Biotech made a strategic collaboration with PulseAI to enhance the former&#39;s recently acquired CGM biosensor technology. Under the collaboration, PulseAI has access to Trinity Biotech&#39;s unique multi-parameter CGM database. Further, the data is used to design and implement Trinity Biotech&#39;s AI-driven health &amp; wellness analytics platform. This platform is a key component in Trinity Biotech&#39;s CGM solution.&nbsp;</p>
<h2>Price Performance of Trinity Biotech</h2>
<p>Year to date, shares of TRIB have lost 17.4% against the industry&#39;s 8.5% growth.</p>
<h2>TRIB&#39;s Zacks Rank and Other Key Picks</h2>
<p>TRIB currently carries a Zacks Rank #2 (Buy).</p>
<p>Some other top-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Boston Scientific </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific currently carries a Zacks Rank #2.</p>
<p>Intuitive Surgical&#39;s shares have surged 58.6% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 earnings per share have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have risen 134% in the past year compared with the industry&#39;s 12.8% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 51.5% compared with the industry&#39;s 15.5% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2334051/will-trinity-biotech-stock-gain-from-its-latest-patent-process?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2334051">To read this article on Zacks.com click here.</a></p>


Penny Stocks

TRIB

Will Trinity Biotech Stock Gain From Its Latest Patent Process?

<p>High-rolling investors have positioned themselves bearish on Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ISRG often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 12 options trades for Intuitive Surgical. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 16% bullish and 66% bearish. Among all the options we identified, there was one put, amounting to $108,150, and 11 calls, totaling $377,465.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $410.0 and $460.0 for Intuitive Surgical, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Intuitive Surgical's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Intuitive Surgical's substantial trades, within a strike price spectrum from $410.0 to $460.0 over the preceding 30 days.</p>
<h3>Intuitive Surgical Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725634917_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/13/24</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$460.00</td>
<td>$108.1K</td>
<td style="text-align: right;">28</td>
<td style="text-align: right;">6</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$96.3</td>
<td>$95.7</td>
<td>$95.7</td>
<td>$410.00</td>
<td>$47.8K</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$96.3</td>
<td>$94.2</td>
<td>$95.15</td>
<td>$410.00</td>
<td>$47.5K</td>
<td style="text-align: right;">34</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$88.7</td>
<td>$86.2</td>
<td>$88.7</td>
<td>$420.00</td>
<td>$44.3K</td>
<td style="text-align: right;">175</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$88.7</td>
<td>$85.8</td>
<td>$88.26</td>
<td>$420.00</td>
<td>$44.1K</td>
<td style="text-align: right;">175</td>
<td style="text-align: right;">5</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Surgical</h3>
<p>Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.</p>
<p>After a thorough review of the options trading surrounding Intuitive Surgical, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Intuitive Surgical's Current Market Status</h3>
<ul>
<li>Trading volume stands at 263,434, with ISRG's price down by -1.66%, positioned at $468.76.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
<h3>What Analysts Are Saying About Intuitive Surgical</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $527.0.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Intuitive Surgical with a target price of $560. </li>
<li>Consistent in their evaluation, an analyst from BTIG keeps a Buy rating on Intuitive Surgical with a target price of $494. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Intuitive Surgical, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Decoding Intuitive Surgical's Options Activity: What's the Big Picture?

<p>Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 15 years by 9.49% on an annualized basis producing an average annual return of 21.17%. Currently, Intuitive Surgical has a market capitalization of $170.67 billion. </p>
<p><strong>Buying $100 In ISRG:</strong> If an investor had bought $100 of ISRG stock 15 years ago, it would be worth <strong>$1,743.35</strong> today based on a price of $480.27 for ISRG at the time of writing.</p>
<h3>Intuitive Surgical's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725564620_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $100 Invested In Intuitive Surgical 15 Years Ago Would Be Worth Today

<p><strong>Phibro Animal Health&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>) delivered adjusted earnings per share of 41 cents in the fourth quarter of fiscal 2024, up 7.9% from the year-ago quarter&#39;s level. The bottom line beat the Zacks Consensus Estimate by 20.6%.</p>
<p>Without adjustments, the GAAP EPS in the quarter was 2 cents, down 92.9% from the year-ago quarter&#39;s figure.</p>
<p>PAHC reported full-year adjusted EPS of $1.19, reflecting a 1.7% decline from fiscal 2023. The figure beat the Zacks Consensus Estimate by 6.25%.</p>
<h2>PAHC&#39;s Net Sales</h2>
<p>In the quarter under review, net sales totaled $273.2 million, up 7.1% from the year-ago quarter&#39;s level. The figure also topped the Zacks Consensus Estimate by 4.1%.</p>
<p>For fiscal 2024, the company reported net sales of $1.02 billion, up 4.1% from the prior-year level. The figure beat the Zacks Consensus Estimate by a marginal 1%.</p>
<h2>Phibro&#39;s Segmental Sales</h2>
<p>The company conducts its operations via three segments &mdash; Animal Health, Mineral Nutrition and Performance Products.</p>
<p>In the fourth quarter of fiscal 2024,&nbsp;<strong>Animal Health</strong>&#39;s net sales increased 8% to $191.5 million. Within the segment, net sales of medicated feed additives (MFAs) and others reflected 12% year-over-year growth. The uptick was driven by the increased demand for MFAs in both domestic and international regions and higher demand for processing aids used in the ethanol fermentation industry. The top line surpassed our model&#39;s projection of $181.8 million by 5.3%.</p>
<p>Nutritional specialty product sales decreased 4%, primarily due to lower demand for dairy products. However, net vaccine sales showed a year-over-year rise of 14%, mostly due to poultry product introductions in Latin America, along with an increase in domestic and international demand.</p>
<p>Net sales in the&nbsp;<strong>Mineral Nutrition</strong>&nbsp;segment rose 6% year over year to $62.1 million due to increased sales volume and higher average selling price. The top line surpassed our model&#39;s projection of $61.9 million by a marginal 0.3%.</p>
<p>Net sales in the&nbsp;<strong>Performance Products</strong>&nbsp;segment fell 1% to $19.6 million as a result of the decreased demand for personal care product ingredients and industrial chemicals. The top line surpassed our model&#39;s projection of $18 million by 8.9%.</p>
<h2>Phibro Animal Health Corporation Price, Consensus and EPS Surprise</h2>
<div class="chart_embed"><img alt="Phibro Animal Health Corporation Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/9c/1724935133.png" style="height:265px; width:577px" title="" /></div>
<div class="chart_embed">Phibro Animal Health Corporation price-consensus-eps-surprise-chart | Phibro Animal Health Corporation Quote</div>
<h2>PAHC&#39;s Margin Performance</h2>
<p>Phibro&#39;s fiscal fourth-quarter gross profit rose 13.8% year over year to $87.2 million. The gross margin expanded 188 basis points (bps) to 31.9% despite a 4.3% rise in the cost of goods sold.</p>
<p>SG&amp;A expenses in the reported quarter were $68.7 million, up 29.9% from the year-ago quarter&#39;s levels. The operating profit declined 21% year over year to $18.5 million and the operating margin contracted 252 bps to 6.8% in the quarter under review.</p>
<h2>PAHC&#39;s Financial Update</h2>
<p>The company exited the fourth quarter of fiscal 2024 with cash and short-term investments of $114.6 million compared with $98.7 million at the end of the fiscal third quarter.</p>
<p>Cumulative net cash provided by operating activities at the end of fiscal 2024 was $87.6 million compared with $13.3 million in the year-ago period.</p>
<h2>Phibro&#39;s Fiscal 2025 Guidance</h2>
<p>The company expects net sales to be between $1.04 billion and $1.09 billion. The Zacks Consensus Estimate for the metric is pegged at $1.25 billion.</p>
<p>Adjusted EPS is expected to be in the range of $1.22-$1.37. The Zacks Consensus Estimate for the same is pegged at $1.43.</p>
<h2>Our Take on Phibro&#39;s Q4 Results</h2>
<p>Phibro delivered better-than-expected revenues and earnings in the reported quarter. The core Animal Health segment benefited from the robust performance of the vaccine, MFAs and other businesses. Additionally, the Mineral Nutrition Products segment reported year-over-year growth.</p>
<p>The anticipated closing of the Zoetis Medicated Feed Additive portfolio acquisition in the coming months may lead to strong earnings accretion. It can also drive investments in the faster-growing vaccines, nutritional specialties and companion animal product segments.</p>
<p>Meanwhile, the contraction of the operating margin in the quarter is discouraging. Declining revenues from the Performance Products segment raise concern.</p>
<h2>PAHC&#39;s Zacks Rank &amp; Other Key Picks</h2>
<p>Phibro currently carries a Zacks Rank #2 (Buy).</p>
<p>Some other top-ranked stocks from the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group&nbsp;and <strong>Quest Diagnostics</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>).</p>
<p>Intuitive Surgical reported a second-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).</p>
<p>Intuitive Surgical has a long-term five-year earnings growth rate of 17.4% compared with the industry&#39;s 13.7%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.</p>
<p>TransMedics, carrying a Zacks Rank #1 at present, reported second-quarter 2024 earnings of 35 cents per share, which surpassed the Zacks Consensus Estimate by 66.7%. Revenues of $114.3 million topped the Zacks Consensus Estimate by 15.9%.</p>
<p>TMDX has an earnings growth rate of 51.7% for 2025 compared with the S&amp;P 500&#39;s 11.3%. The company beat on earnings in each of the trailing four quarters, the average surprise being 287.50%.</p>
<p>Quest Diagnostics, carrying a Zacks Rank #2 (Buy) at present, reported a second-quarter adjusted EPS of $2.35, which surpassed the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion outpaced the Zacks Consensus Estimate by 0.5%.</p>
<p>DGX has a historical five-year earnings growth rate of 7.4% compared with the industry&#39;s 4.2%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%.</p>
<p><a href="https://www.zacks.com/stock/news/2328933/phibro-q4-earnings-and-revenues-beat-operating-margin-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-2328933">To read this article on Zacks.com click here.</a></p>


PAHC

Phibro Q4 Earnings and Revenues Beat, Operating Margin Down

<p><strong>Neogen</strong>&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neog#NASDAQ">NEOG</a>) vast international trade is impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell).</p>
<p>Neogen&#39;s international business continues to be affected by currency movements.</p>
<p>The current macroeconomic environment has adversely impacted Neogen&#39;s financial operations. Governments and insurance companies continue to look for ways to contain the rising cost of healthcare. This might put pressure on players in the healthcare industry, with Neogen being no exception.&nbsp; Although the company is gradually coming out of the impact of the two-and-a-half-year-long pandemic, deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor cost as well as freight charges, and a higher interest rate have put the medical device space in a tight spot.</p>
<p>With sustained macroeconomic pressure, the company may struggle to keep its cost of revenues and operating expenses in check. In fiscal 2024, sales and marketing expenses rose 29.5% year over year. Our model forecasts a 1.5% rise in the metric for fiscal 2025.</p>
<p>Further, Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition resulting from the development of new technologies by the company&#39;s competitors, which could affect the marketability and profitability of Neogen&#39;s products.</p>
<h2>Factors That May Offset the Risks for NEOG Stock</h2>
<p>Neogen is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets. In the fiscal fourth quarter, the Indicator Testing, Culture Media &amp; Other product categories benefited from double-digit growth in the Petrifilm product line as well as solid growth in culture media and food quality nutritional analysis. Additionally, the Vet Instruments and Disposables product line witnessed solid core growth. In the Animal care and other product category, core growth was led by higher sales of vitamin injectables and Biologics products.</p>
<div class="chart_embed">
<h2>Neogen Corporation Price</h2>
<p><img alt="Neogen Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/a6/1724841357.png" style="height:251px; width:538px" title="" /></p>
<p>Neogen Corporation price | Neogen Corporation Quote</p>
<p>Neogen also continues to carry out its strong R&amp;D activities. During the fiscal fourth quarter, Neogen&#39;s R&amp;D expenses totaled $5.1 million, up sequentially 4.1%.</p>
</div>
<p>The company is expanding well in other geographies. The company is seeing double-digit sales growth in Latin America, with strong performance across most key product categories.&nbsp; The business in Europe and Asia Pacific grew in low single digits and mid-single digits, respectively, with strength in Culture media, Petrifilm, General Sanitation and Sample Handling.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Boston Scientific </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific currently carries a Zacks Rank of 2 (Buy).</p>
<p>Intuitive Surgical&#39;s shares have surged 55.4% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 earnings per share have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have risen 174.1% in the past year compared with the industry&#39;s 9.2% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 46% compared with the industry&#39;s 9.2% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2328483/neogen-suffers-from-competitive-pressure-macroeconomic-woes?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2328483">To read this article on Zacks.com click here.</a></p>


NEOG

Neogen Suffers From Competitive Pressure, Macroeconomic Woes

<p>BTIG  analyst Ryan Zimmerman   maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and raises the price target from $469 to $494.</p>


BTIG Maintains Buy on Intuitive Surgical, Raises Price Target to $494

<p><strong>ICON plc&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iclr#NASDAQ">ICLR</a>) is well-poised to grow in the coming quarters, driven by its meaningful strategic additions. The company is committed to improving patient access and engagement strategy. Meanwhile, concerns about the adverse macroeconomic impacts as well as currency fluctuations remain, which may hamper ICON&#39;s performance.</p>
<p>In the past year, this Zacks Rank #3 (Hold) company has gained 27% compared with the&nbsp;industry&#39;s 9.9% growth and 27.1% rise of the S&amp;P 500 composite.</p>
<p>The leading healthcare intelligence and clinical research organization has a market capitalization of $26.85 billion. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.92%.</p>
<p>Let&#39;s delve deeper.</p>
<h2>Tailwinds</h2>
<p><strong>Focus on Patient Access &amp; Engagement Strategy: </strong>ICON is continuously improving in site identification, study placement and patient recruitment and retention through its focused patient, site and data strategy.</p>
<p>In line with this, Accellacare, ICON&#39;s global clinical research network, is offering customers a wide range of stand-alone and integrated solutions at the site or in patients&#39; homes as part of decentralized trials. One of the key strategic moves of ICON in 2024 was a focused rebranding of its specialized biotech solutions division, ICON Biotech.</p>
<p>During the second quarter of 2024, the company experienced positive constructive progress in the biotech funding area.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/34/75344.jpg?v=190607711" /></p>
<p>Image Source: Zacks Investment Research</p>
<p><strong>Strategic Pacts to Drive Growth:&nbsp;</strong>ICON is focused on expanding its business through strategic acquisitions and partnerships. The company&#39;s acquisition of HumanFirst in January 2024 is strategically aligned with its approach to provide an enhanced integrated offering.</p>
<p>ICON also partnered with the U.S. Biomedical Advanced Research and Development Authority to execute a clinical trial to evaluate the effectiveness of the next-generation COVID vaccine candidates.</p>
<h2>Headwinds</h2>
<p><strong>Macroeconomic Pressure:&nbsp;</strong>Inflation and rising labor costs could increase the cost of ICON&#39;s services, which it may not be able to recover from its customers. A sustained increase in these costs may require the company to hike the price of service offerings. These actions could adversely affect its future revenues, gross margin or both. In the second quarter, ICON registered an increase of 4.5% in the direct cost.</p>
<p><strong>Foreign Exchange Translation:&nbsp;</strong>Foreign exchange is a major headwind for ICON as it prepares its financial statements in U.S. dollars while some of its subsidiaries operate in other currencies like the pound sterling and the euro. In addition, the company&#39;s contracts with clients, as well as expenses, are in various local currencies, thus exposing it to fluctuations in exchange rates. These could have an adverse effect on ICLR&#39;s financial results. In the second quarter, ICON registered a net foreign exchange loss of $3.3 million.</p>
<h2>Estimate Trend</h2>
<p>The Zacks Consensus Estimate for ICON&#39;s 2024 earnings per share has remained constant at $15.09 in the past 30 days.</p>
<p>The consensus estimate for 2024 revenues is pegged at $8.51 billion. This indicates a 4.8% rise from the year-ago reported number.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are&nbsp;<strong>TransMedix Group</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>),&nbsp;<strong>Intuitive Surgical </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>) and <strong>Boston Scientific</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>).</p>
<p>TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. The company&#39;s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Its shares have gained 187.6% compared with the industry&#39;s 12.6% growth in the past year.</p>
<p>TMDX sports a Zacks Rank #1 (Strong Buy) at present.</p>
<p>Intuitive Surgical, sporting a Zacks Rank of 1 at present, has an estimated long-term earnings growth rate of 17.4% compared with the industry&#39;s 13.7%. Shares of the company have gained 61.4% compared with the industry&#39;s 12.5% growth over the past year.</p>
<p>ISRG&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.</p>
<p>Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated earnings growth rate of 17.1% for 2024 compared with the industry&#39;s 15.7%. Shares of the company have gained 47.1% compared with the industry&#39;s 13.8% growth over the past year.</p>
<p>BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.</p>
<p><a href="https://www.zacks.com/stock/news/2326915/reasons-to-retain-icon-iclr-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2326915">To read this article on Zacks.com click here.</a></p>


Contracts

ICLR

Reasons to Retain ICON Stock in Your Portfolio Now

Intuitive Surgical Offers Low Risk, High Return Despite Valuation Concerns

Intuitive Surgical: A Growth Machine - But Valuation? That's Another Story

Intuitive Surgical Stock Is Too Hot To Touch

Stocks that are set to benefit from either Harris or Trump winning scenarios – Barclays

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intuitive Surgical (ISRG – Research Report), HCA H...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), HCA Healthcare (HCA) and Teleflex (TFX)

Intuitive Surgical (ISRG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Travis Steed ...

Buy Rating on Intuitive Surgical: Economic and Performance Advantages of the da Vinci 5 Robotic System

BTIG analyst Ryan Zimmerman has maintained their bullish stance on ISRG stock, giving a Buy rating on September 26. Ryan Zimmerman has given his Bu...

Buy Rating on Intuitive Surgical: Expanding Robotic Surgery into Emergency Procedures Promises Market Growth

The COVID-19 pandemic made the world realize the importance of investing in healthcare infrastructure and developing treatments for unmet medical n...

LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Street's "Strong Buy" Rating?

Intuitive Surgical ($ISRG), the world leader in robotic surgery, is likely to experience downside volatility over the next 12 months before long-te...

Intuitive Surgical Faces Volatility Ahead of Long-Term Growth

Deutsche Bank analyst Imron Zafar maintained a Hold rating on Intuitive Surgical (ISRG – Research Report) today and set a price target of $445.00. ...

Comments

Intuitive Surgical

Intérêt court

Intuitive Surgical (NASDAQ:ISRG) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL